ORIC Pharmaceuticals Inc
Company Overview
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. The company's pipeline includes multiple programs targeting various mechanisms of cancer resistance. Their lead product candidate, ORIC-533, is a CD73 inhibitor being developed for multiple myeloma and other hematologic cancers.
The company is currently in the research and development phase, with no commercial products yet available on the market. Their business model focuses on discovering and developing novel therapies rather than generating immediate revenue.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate ORIC Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.